AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

AbCellera Biologics (NASDAQ:ABCL) issued its earnings results on Monday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04, FiscalAI reports. The company had revenue of $10.64 million for the quarter, compared to analysts’ expectations of $8.41 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%.

Here are the key takeaways from AbCellera Biologics’ conference call:

• AbCellera reported strong four-week Phase II results for ABCL635, with an 83% reduction in daily moderate-to-severe hot flashes versus 33% on placebo, and no clear gastrointestinal or liver-toxicity signal. The company cautioned that the study assessed a single dose and that comparisons with other treatments are cross-trial.
• The company plans to advance ABCL635 into late-stage development in 2027 and expects to release 12-week and open-label extension data in early 2027. It also plans to study the drug for treatment-related hot flashes in breast and prostate cancer patients, while a longer-acting follow-on, ABCL992, entered IND-enabling work.
• After completing an oversubscribed $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and over $890 million in available liquidity including committed government funding. Management said it has funding for at least three years of pipeline investment.
• AbCellera added three programs—ABCL992, an oncology program, and an ion-channel-targeting antibody—and said ABCL688 and ABCL386 remain in IND-enabling work, with both potentially entering clinical trials in 2027.
• Despite favorable Phase I tolerability and pharmacokinetic results for ABCL575, AbCellera does not plan to advance it beyond Phase I, citing setbacks for other drugs targeting the OX40/OX40L pathway.

AbCellera Biologics Price Performance

ABCL traded up $0.62 during trading on Monday, hitting $12.50. 2,945,557 shares of the stock traded hands, compared to its average volume of 5,858,420. The firm has a market capitalization of $3.83 billion, a P/E ratio of -23.15 and a beta of 1.59. AbCellera Biologics has a 12-month low of $2.74 and a 12-month high of $15.02. The firm has a 50-day moving average of $12.28 and a 200 day moving average of $7.04.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ABCL shares. Cantor Fitzgerald raised their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Jefferies Financial Group started coverage on AbCellera Biologics in a research note on Friday, October 30th. They issued a “buy” rating and a $21.00 target price for the company. Truist Financial increased their target price on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. UBS Group assumed coverage on AbCellera Biologics in a report on Monday, October 12th. They set a “buy” rating and a $18.00 target price for the company. Finally, JPMorgan Chase & Co. initiated coverage on AbCellera Biologics in a research report on Tuesday, September 29th. They set an “overweight” rating and a $17.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AbCellera Biologics presently has a consensus rating of “Moderate Buy” and an average target price of $15.78.

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease.

The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.